

Pharmaceuticals & Medical Devices Bureau of India  
Balance Sheet As At 31 March, 2022

Particulars	Notes no.	As at	As at
		31 March, 2022	31 March, 2021
		Amount in Rs.	Amount in Rs.
<b>I Trust funds / corpus</b>			
Contribution of CPSUs	1	75,00,000	75,00,000
<b>Reserve and Surplus</b>	2	3,51,39,94,252	2,54,59,09,205
<b>Current liabilities</b>			
Trade payables	3	1,01,85,33,234	43,92,11,238
Others liabilities	4	1,12,52,97,281	53,61,47,793
<b>Total</b>		<b>5,66,53,24,767</b>	<b>3,52,87,68,236</b>
<b>II Assets</b>			
<b>Non-current assets</b>			
Fixed assets	5		
(I) Tangible assets		84,00,613	70,84,072
(II) Intangible assets		5,39,349	5,50,640
<b>Current assets</b>			
Inventories	6	1,46,46,17,229	1,05,05,35,529
Trade receivables	7	1,19,75,44,395	1,43,71,68,906
Cash and cash equivalents	8	2,67,26,89,034	92,66,07,972
Short-term loans and advances	9	1,15,96,840	34,63,687
Other current assets	10	30,99,37,306	10,33,57,430
<b>Total</b>		<b>5,66,53,24,767</b>	<b>3,52,87,68,236</b>
<b>III Accompanying Notes Forming Part of Financial Statements</b>	1 - 34		

As per our report of even date  
For APRA and Associates LLP  
Chartered Accountants  
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-  
Arun Kumar Gupta  
Designated Partner  
Membership No.: 089657

Sd/-  
General Manager (F & A)

Sd/-  
CEO & Secretary General

Place: New Delhi  
Date: 29-09-2022

Pharmaceuticals & Medical Devices Bureau of India  
Statement Of Profit And Loss For The Year Ended 31 March 2022

Particulars	Notes No	Year ended	Year ended
		31 March, 2022	31 March, 2021
		Amount in Rs.	Amount in Rs.
Revenue from operations	11	5,67,57,93,922	4,30,09,73,403
Other income	12	26,74,81,397	14,23,03,229
Grant in Aid (General)		68,50,00,000	65,00,00,000
<b>I Total revenue</b>		<b>6,62,82,75,319</b>	<b>5,09,32,76,632</b>
<b>Expenses:</b>			
Cost of goods purchased	13	4,56,74,12,930	3,45,62,53,215
Change in inventories (finished goods)	14	(41,40,81,701)	(5,93,29,767)
Employee benefit expenses	15	7,63,49,427	6,20,31,155
Finance cost	16	70,255	1,11,785
Depreciation and amortization expense	5	21,20,806	21,60,549
Other expenses	17	1,20,97,88,835	1,01,05,09,460
<b>II Total expenses</b>		<b>5,44,16,60,552</b>	<b>4,47,17,36,397</b>
<b>III Profit / (Loss) before tax ( I-II )</b>		<b>1,18,66,14,767</b>	<b>62,15,40,235</b>
<b>IV Current Tax</b>		21,85,29,720	1,64,46,887
<b>V Profit / (Loss) Carried forward to BS ( III-IV)</b>		<b>96,80,85,047</b>	<b>60,50,93,348</b>

Accompanying Notes Forming Part of 1 - 34  
Financial Statements

As per our report of even date  
For APRA and Associates LLP  
Chartered Accountants  
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-

Arun Kumar Gupta  
Designated Partner  
Membership No.: 089657

Place: New Delhi  
Date: 29-09-2022

Sd/-

General Manager (F & A)

Sd/-

CEO & Secretary General